efbemalenograstim alfa sold brand name ryzneuta medication used decrease incidence infection chemotherapyinduced leukocyte growth given subcutaneous approved medical use china may united states november efbemalenograstim alfa indicated decrease incidence infection manifested febrile neutropenia adults nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated clinically significant incidence febrile pharmacologyrelated article stub help wikipedia expanding httpsenwikipediaorgwikiefbemalenograstimalfa